Valproate as monotherapy for juvenile myoclonic epilepsy: Dose-effect study

Therapeutic Drug Monitoring

Volumn 20, Issue 2, 1998, Pages 149-157

  Sundqvist, Anders ^a   Tomson, Torbjörn ^a   Lundkvist, Birgitta ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Epilepsy; Monotherapy; Pharmacotherapy; Valproic acid

Indexed keywords

VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; FEMALE; GRAND MAL EPILEPSY; HUMAN; MALE; MYOCLONUS EPILEPSY; NEUROPSYCHOLOGICAL TEST; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 0031957119     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199804000-00004     Document Type: Article

References (31)

1. Gram L, Flachs H, Würtz-Jorgensen A, Parnas J, Andersen B. Sodium valproate, serum level and clinical effect in epilepsy: a controlled study. Epilepsia 1979;20:303-12.
2. Turnbull DM, Rawlins MD, Weightman D, Chadwick DW. Plasma concentrations of sodium valproate: their clinical value. Ann Neurol 1983;14:38-42.
3. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489-501.
4. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389-99.
5. Schmidt D, Haenel F. Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine: Individual variation in relation to seizure frequency and type. Neurology 1984;34:1252-5.
6. Turnbull DM, Rawlins MD, Weightman D, Chadwick DW. "Therapeutic" serum concentration of phenytoin: the influence of seizure type. J Neurol Neurosurg Psychiatry 1984;47:231-4.
7. Chadwick DW. Concentration-effect relationships of valproic acid. Clin Pharmacokinet 1985;10:155-63.
8. Bourgeois B. Valproic acid, clinical use. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. 4th ed. NY: Raven Press, 1995;633-9.
9. Fariello RG, Varasi M, Smith MC. Valproic acid, mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs. 4th ed. New York: Raven Press, 1995;581-8.
10. Bourgeois B, Beaumanoir A, Blajev B, et al. Monotherapy with valproate in primary generalized epilepsies. Epilepsia 1987;28 (suppl 2):S8-S11.
11. Rowan AJ, Binnie CD, Warfield CA, Meinardi H, Meijer JWA. The delayed effect of sodium valproate on the photoconvulsive response in man. Epilepsia 1979;20:61-8.
12. Sundqvist A, Tomson T, Lundkvist B. Pharmacokinetics of valproic acid in patients with juvenile myoclonic epilepsy on monotherapy. Ther Drug Monit 1997;19:153-9.
13. Leppik IE. Compliance during treatment of epilepsy. Epilepsia 1988;29(suppl 2):S79-S84.
14. Leppik IE. Variability of phenytoin, carbamazepine and valproate concentrations in a clinic population. Epilepsy Res Suppl 1988;1: 85-90.
15. Janz D. Epilepsy with impulsive petit mal (juvenile myoclonic epilepsy). Acta Neurol Scand 1985;72:449-59.
16. Sundqvist A. Juvenile myoclonic epilepsy: events before diagnosis. J Epilepsy 1990;3:189-92.
17. Aldenkamp AP, Alpherts WCJ, Blennow G, et al. Withdrawal of antiepileptic medication in children - effects on cognitive function: the multicenter Holmfrid study. Neurology 1993;43:41-50.
18. Serratosa JM, Delgado-Escueta AV, Medina MT, Zhang Q, Iranmanesh R, Sparkes RS. Clinical and genetic analysis of a large pedigree with juvenile myoclonic epilepsy. Ann Neurol 1996;39: 187-95.
19. Whitehouse WP, Rees M, Curtis D, et al. Linkage analysis of idiopathic generalised epilepsy and and marker loci on chromosome 6p in families of patients with juvenile myoclonic epilepsy: no evidence for an epilepsy locus in the HLA region. Am J Hum Genet 1993;53:652-62.
20. Simonsen N. Juvenil myoklon epilepsi. Ugeskr Laeg 1975;137: 2400-2.
21. Asconapé J, Kiffin Penry J. Some clinical and EEG aspects of benign juvenile myoclonic epilepsy. Epilepsia 1984;25(1):108-14.
22. Covanis A, Gupta AK, Jeavons PM. Sodium valproate: Monotherapy and polytherapy. Epilepsia 1982;23:693-720.
23. Delgado-Escueta AV, Enrile-Bacsal F. Juvenile myoclonic epilepsy of Janz. Neurology 1984;34:285-94.
24. Braathen G, Theorell K, Persson A, Rane A. Valproate in the treatment of absence epilepsy in children: a study of dose-response relationships. Epilepsia 1988;29(5):548-52.
25. Beydoun A, Sackellares JC, Shu V, the Depakote Monotherapy for Partial Seizures Study Group. Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: a double-blind, concentration-response design clinical trial. Neurology 1997;48:182-8.
26. Loiseau P, Cenraud B, Levy RH, Akbaraly R, Brachet-Liermain A, Guyot M, Morselli PL. Diurnal variations in steady state plasma concentrations of valproic acid in epileptic patients. Clin Pharmacokinet 1982;7:544-52.
27. Snead OC, Hosey LC. Exacerbation of seizures in children by carbamazepine. N Engl J Med 1985;313:916-21.
28. Gram L, Wulff K, Rasmussen KE, et al. Valproate sodium: a controlled clinical trial including monitoring of drug levels. Epilepsia 1977;18(2):144-8.
29. Mattson RH, Cramer JA, Collins JF, the VA Epilepsy Cooperative Group. Early tolerance to antiepileptic drug side effects: a controlled trial of 247 patients. In: Koella WP, Frey HH, Fröscher W, Meinardi, eds. Tolerance to Beneficial and Adverse Effects of Antiepileptic Drugs. NY: Raven Press, 1986;149-56
30. Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984;70:65-9.
31. Trimble MR, Thompson PJ. Sodium valproate and cognitive function. Epilepsia 1984;25(suppl 1):S60-S64.